Sutro Biopharma (STRO) Total Liabilities (2017 - 2026)
Sutro Biopharma (STRO) posted Total Liabilities of $306.3 million for Q4 2025, up 3.15% sequentially from $296.9 million in Q3 2025, and down 10.6% YoY from $342.6 million in Q4 2024.
Sutro Biopharma (STRO) Total Liabilities (2017 - 2026) Analysis & Trends
Sutro Biopharma has reported Total Liabilities for 9 years, with the latest figure at $306.3 million in Q4 2025.
- Quarterly Total Liabilities fell 10.6% year-over-year to $306.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $306.3 million (down 10.6% YoY) and the FY2025 annual result came in at $306.3 million, down 10.6% from the prior year.
- Total Liabilities grew to $306.3 million in Q4 2025 per STRO's latest filing, from $296.9 million in the prior quarter.
- Over five years, Total Liabilities peaked at $347.2 million in Q1 2025 and troughed at $51.2 million in Q1 2021.
- A 5-year average of $229.7 million and a median of $295.7 million in 2025 frame the typical range for Total Liabilities.
- The sharpest annual moves came in 2021 and 2022: Total Liabilities dropped 28.69% in 2021, then soared 237.67% in 2022.
- Over 5 years, Total Liabilities stood at $88.8 million in 2021, then soared by 113.74% to $189.9 million in 2022, then surged by 69.09% to $321.1 million in 2023, then rose by 6.7% to $342.6 million in 2024, then fell by 10.6% to $306.3 million in 2025.
- According to Business Quant data, Total Liabilities over the past three periods registered $306.3 million, $296.9 million, and $294.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Sutro Biopharma | 339.58 Mn | 175.24 Mn | - | 297.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 297.78 Mn |
| Dec 31, 2025 | 306.28 Mn |
| Sep 30, 2025 | 296.93 Mn |
| Jun 30, 2025 | 294.47 Mn |
| Mar 31, 2025 | 347.24 Mn |
| Dec 31, 2024 | 342.61 Mn |
| Sep 30, 2024 | 340.61 Mn |
| Jun 30, 2024 | 336.87 Mn |
| Mar 31, 2024 | 305.38 Mn |
| Dec 31, 2023 | 321.09 Mn |
| Sep 30, 2023 | 319.39 Mn |
| Jun 30, 2023 | 310.18 Mn |
| Mar 31, 2023 | 172.60 Mn |
| Dec 31, 2022 | 189.90 Mn |
| Sep 30, 2022 | 170.97 Mn |
| Jun 30, 2022 | 176.56 Mn |
| Mar 31, 2022 | 83.30 Mn |
| Dec 31, 2021 | 88.84 Mn |
| Sep 30, 2021 | 87.89 Mn |
| Jun 30, 2021 | 52.29 Mn |